Affiliation:
1. Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy
2. Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-Universitaria di Modena, Ospedale Civile di Baggiovara, Modena, Italy
3. Endocrinology Unit, AUSL-IRCCS of Reggio Emilia, Reggio Emilia, Italy
Abstract
Abstract
Context
Although sexuality influences well-being and quality of life (QoL), studies on sexual dysfunction (SD) in adult growth hormone deficiency (AGHD) patients are lacking.
Objective
To investigate the prevalence of SD in AGHD patients grouped according to recombinant human growth hormone (r-hGH) therapy.
Design
Prospective, cross-over, 24 months, monocentric study.
Setting
Real-life clinical setting in a tertiary, endocrinological center.
Patients
83 AGHD patients (31 women, 52 men, mean age 56.3 ± 14.7 years) were enrolled according to stringent criteria.
Intervention(s)
Patients already on long-term r-hGH therapy (Group 1, n = 32) vs untreated (Group 2, n = 51).
Main outcome measure(s)
Serum hormones, QoL Satisfaction in Hypopituitarism (QLS-H) and QoL Assessment of GHD in Adults (QoL-AGHDA) questionnaires for QoL, Index for Erectile Function-15 (IIEF-15) in men, and Female Sexual Function Index (FSFI) in women for SD.
Results
The overall prevalence of SD was 71.2% (60% men, 89% women). All IIEF-15 scores were lower (P = 0.001) and erectile dysfunction was more prevalent in Group 2 (75%) than Group 1 (35%). IGF-1 was correlated to scores of all IIEF-15 domains, particularly with that of erectile function (EF) (R2=0.123, P = 0.019). EF domain score correlated with QLS-H (P < 0.005) and QoL-AGHDA (P = 0.001). Despite the high prevalence of female SD also in untreated AGHD women, FSFI scores did not correlate with IGF-1 levels and QoL scores.
Conclusions
SD is highly prevalent in AGHD patients, especially in those untreated. SD represents an overlooked and neglected issue in AGHD, regardless the contribution of sexual life on QoL. The evaluation of sexual function should be integrated in the global assessment of AGHD patients.
Subject
Endocrinology, Diabetes and Metabolism
Reference50 articles.
1. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia;Ho;Eur J Endocrinol.,2007
2. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline;Molitch;J Clin Endocrinol Metab.,2011
3. Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H);Rosilio;J Clin Endocrinol Metab.,2004
4. KIMS Study Group and the KIMS International Board. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults.;Bengtsson;J Clin Endocrinol Metab.,1999
5. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status: 3-year results from the HypoCCS database;Attanasio;J Clin Endocrinol Metab.,2002
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献